

Jinru Shia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4479101/publications.pdf>

Version: 2024-02-01

313
papers

24,337
citations

4960

84
h-index

9345

143
g-index

321
all docs

321
docs citations

321
times ranked

25048
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathological evaluation of a rectal endoscopic submucosal dissection specimen using micro-computed tomography. <i>Endoscopy</i> , 2022, 54, E254-E255.	1.8	4
2	Preoperative systemic chemotherapy alters the histopathological growth patterns of colorectal liver metastases. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 48-64.	3.0	23
3	Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome. <i>Clinical Cancer Research</i> , 2022, 28, 404-413.	7.0	13
4	Gastrointestinal stromal tumors (GISTs) arising in uncommon locations: clinicopathologic features and risk assessment of esophageal, colonic, and appendiceal GISTs. <i>Modern Pathology</i> , 2022, 35, 554-563.	5.5	9
5	Effectiveness of a surveillance program of upper endoscopy for upper gastrointestinal cancers in Lynch syndrome patients. <i>International Journal of Colorectal Disease</i> , 2022, 37, 231-238.	2.2	8
6	Stratification of chemotherapy-treated stage III colorectal cancer patients using multiplexed imaging and single-cell analysis of T-cell populations. <i>Modern Pathology</i> , 2022, 35, 564-576.	5.5	12
7	MRI at Restaging After Neoadjuvant Therapy for Rectal Cancer Overestimates Circumferential Resection Margin Proximity as Determined by Comparison With Whole-Mount Pathology. <i>Diseases of the Colon and Rectum</i> , 2022, 65, 489-496.	1.3	9
8	Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. <i>Oncologist</i> , 2022, 27, 380-388.	3.7	12
9	Identification of a Subset of Stage I Colorectal Cancer Patients with High Recurrence Risk. <i>Journal of the National Cancer Institute</i> , 2022, , .	6.3	1
10	<i>ATM</i> Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 761-770.	6.3	3
11	Early age of onset and broad cancer spectrum persist in MSH6- and PMS2-associated Lynch syndrome. <i>Genetics in Medicine</i> , 2022, 24, 1187-1195.	2.4	7
12	Same-Cell Co-Occurrence of RAS Hotspot and BRAF V600E Mutations in Treatment-Naive Colorectal Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100365.	3.0	1
13	Mouse characteristics that affect establishing xenografts from hepatocellular carcinoma patient biopsies in the United States. <i>Cancer Medicine</i> , 2022, 11, 602-617.	2.8	1
14	Pathological Evaluation of Rectal Cancer Specimens Using Micro-Computed Tomography. <i>Diagnostics</i> , 2022, 12, 984.	2.6	2
15	Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes. <i>Oncolmmunology</i> , 2022, 11, 2054757.	4.6	3
16	Acellular mucin in lymph nodes isolated from treatment-naïve colorectal cancer resections: a clinicopathologic analysis of 16 cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, , .	2.8	0
17	PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2363-2376.	27.0	588
18	Intraoperative opioids are associated with decreased recurrence rates in colon adenocarcinoma: a retrospective observational cohort study. <i>British Journal of Anaesthesia</i> , 2022, 129, 172-181.	3.4	9

#	ARTICLE	IF	CITATIONS
19	Primary Clonal Loss of Mismatch Repair Protein on Immunohistochemistry: A Pattern of Abnormality That Warrants Genetic Workup. <i>JCO Precision Oncology</i> , 2022, , .	3.0	1
20	Detecting mismatch repair deficiency in solid neoplasms: immunohistochemistry, microsatellite instability, or both?. <i>Modern Pathology</i> , 2022, 35, 1515-1528.	5.5	13
21	Hepatocellular carcinoma in patients with no identifiable risk factors. <i>Hpb</i> , 2021, 23, 118-126.	0.3	4
22	The diversity of tumours with microsatellite instability: molecular mechanisms and impact upon microsatellite instability testing and mismatch repair protein immunohistochemistry. <i>Histopathology</i> , 2021, 78, 485-497.	2.9	32
23	Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1429-1437.	7.0	23
24	Three-Dimensional Vessel Segmentation in Whole-Tissue and Whole-Block Imaging Using a Deep Neural Network. <i>American Journal of Pathology</i> , 2021, 191, 463-474.	3.8	7
25	Concept of Complete Mesocolic Excision and the Role of Computed Tomography Imaging. <i>Seminars in Roentgenology</i> , 2021, 56, 201-205.	0.6	0
26	Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 130-133.	4.9	14
27	Prevalence and Characterization of Biallelic and Monoallelic <i>NTHL1</i> and <i>MSH3</i> Variant Carriers From a Pan-Cancer Patient Population. <i>JCO Precision Oncology</i> , 2021, 5, 455-465.	3.0	10
28	Histopathological Growth Patterns and Survival After Resection of Colorectal Liver Metastasis: An External Validation Study. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab026.	2.9	28
29	Reply to Singh et al.. <i>Modern Pathology</i> , 2021, 34, 1033-1034.	5.5	1
30	Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 911-919.	1.6	34
31	Initial evaluation of dual-energy computed tomography as an imaging biomarker for hepatic metastases from neuroendocrine tumor of the gastrointestinal tract. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 2085-2092.	2.0	1
32	Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant <i>POLE/POLD1</i> Colon Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 817-826.	3.0	18
33	KRAS mutant rectal cancer cells interact with surrounding fibroblasts to deplete the extracellular matrix. <i>Molecular Oncology</i> , 2021, 15, 2766-2781.	4.6	7
34	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1683-1692.	6.3	66
35	Identification of a TP53 Deletion in an Undifferentiated Embryonal Sarcoma of the Liver Provides Clinically Relevant Longitudinal Detection of Circulating Tumor DNA. <i>JCO Precision Oncology</i> , 2021, 5, 1421-1425.	3.0	1
36	Clinicopathologic Features of Varicella Zoster Virus Infection of the Upper Gastrointestinal Tract. <i>American Journal of Surgical Pathology</i> , 2021, 45, 209-214.	3.7	5

#	ARTICLE	IF	CITATIONS
37	OUP accepted manuscript. American Journal of Clinical Pathology, 2021, , .	0.7	1
38	Treatment of Platinum Nonresponsive Metastatic Malignant Peritoneal Mesothelioma With Combination Chemoimmunotherapy. Journal of Immunotherapy, 2021, Publish Ahead of Print, .	2.4	3
39	The context-specific role of germline pathogenicity in tumorigenesis. Nature Genetics, 2021, 53, 1577-1585.	21.4	44
40	Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. Nature Communications, 2021, 12, 6821.	12.8	15
41	Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery. JAMA Network Open, 2021, 4, e2133457.	5.9	16
42	Micro-computed tomography: A novel diagnostic technique for the evaluation of gastrointestinal specimens. Endoscopy International Open, 2021, 09, E1886-E1889.	1.8	1
43	Prediction of Recurrence Patterns from Hepatic Parenchymal Disease After Resection of Colorectal Liver Metastases. Annals of Surgical Oncology, 2020, 27, 188-195.	1.5	6
44	DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. Modern Pathology, 2020, 33, 648-656.	5.5	90
45	Pathology definitions and resection strategies for early colorectal neoplasia: Eastern versus Western approaches in the post-Vienna era. Gastrointestinal Endoscopy, 2020, 91, 983-988.	1.0	9
46	Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes. Modern Pathology, 2020, 33, 871-879.	5.5	58
47	Histopathological growth patterns and positive margins after resection of colorectal liver metastases. Hpb, 2020, 22, 911-919.	0.3	23
48	Acellular mucin in pseudomyxoma peritonei of appendiceal origin: what is adequate sampling for histopathology?. Journal of Clinical Pathology, 2020, 73, 220-222.	2.0	11
49	Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies. Familial Cancer, 2020, 20, 201-213.	1.9	8
50	Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases. Clinical and Experimental Metastasis, 2020, 37, 593-605.	3.3	27
51	Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver. Cancer, 2020, 126, 4126-4135.	4.1	5
52	Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer. Oncoimmunology, 2020, 9, 1841948.	4.6	3
53	DEAD-box RNA helicase protein DDX21 as a prognosis marker for early stage colorectal cancer with microsatellite instability. Scientific Reports, 2020, 10, 22085.	3.3	12
54	Confirmation of complete mesocolic excision with central vascular ligation. European Journal of Surgical Oncology, 2020, 46, 1386-1387.	1.0	1

#	ARTICLE	IF	CITATIONS
55	Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2020, 25, e1825-e1836.	3.7	13
56	Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3271-3279.	7.0	118
57	Maspin as a Prognostic Marker for Early Stage Colorectal Cancer With Microsatellite Instability. <i>Frontiers in Oncology</i> , 2020, 10, 945.	2.8	11
58	Smooth muscle tumors of the gastrointestinal tract: an analysis of prognostic features in 407 cases. <i>Modern Pathology</i> , 2020, 33, 1410-1419.	5.5	13
59	L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer. <i>Nature Cancer</i> , 2020, 1, 28-45.	13.2	137
60	STAT1 as a potential prognosis marker for poor outcomes of early stage colorectal cancer with microsatellite instability. <i>PLoS ONE</i> , 2020, 15, e0229252.	2.5	22
61	Prolyl 4-hydroxylase alpha 1 protein expression risk-stratifies early stage colorectal cancer. <i>Oncotarget</i> , 2020, 11, 813-824.	1.8	7
62	Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases. <i>European Radiology</i> , 2019, 29, 458-467.	4.5	10
63	Somatic HNF1A mutations in the malignant transformation of hepatocellular adenomas: a retrospective analysis of data from MSK-IMPACT and TCGA. <i>Human Pathology</i> , 2019, 83, 1-6.	2.0	14
64	Predictive Markers Require Thorough Analytic Validation. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 907-909.	2.5	1
65	Mathematical Modeling of the Metastatic Colorectal Cancer Microenvironment Defines the Importance of Cytotoxic Lymphocyte Infiltration and Presence of PD-L1 on Antigen Presenting Cells. <i>Annals of Surgical Oncology</i> , 2019, 26, 2821-2830.	1.5	21
66	A rectal cancer organoid platform to study individual responses to chemoradiation. <i>Nature Medicine</i> , 2019, 25, 1607-1614.	30.7	320
67	Contemporary Validation of a Nomogram Predicting Colon Cancer Recurrence, Revealing All-Stage Improved Outcomes. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz015.	2.9	16
68	Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade. <i>Modern Pathology</i> , 2019, 32, 1551-1562.	5.5	12
69	Evaluation of diffusion kurtosis and diffusivity from baseline staging MRI as predictive biomarkers for response to neoadjuvant chemoradiation in locally advanced rectal cancer. <i>Abdominal Radiology</i> , 2019, 44, 3701-3708.	2.1	7
70	Majority of <i>B2M</i> -Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	3.0	61
71	Immunotherapy in colorectal cancer: rationale, challenges and potential. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 361-375.	17.8	1,039
72	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 286-295.	1.6	397

#	ARTICLE	IF	CITATIONS
73	Variation in the Thoroughness of Pathologic Assessment and Response Rates of Locally Advanced Rectal Cancers After Chemoradiation. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 794-799.	1.7	2
74	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. <i>Modern Pathology</i> , 2019, 32, 110-121.	5.5	28
75	SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance. <i>Clinical Cancer Research</i> , 2019, 25, 1948-1956.	7.0	71
76	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. <i>JAMA Oncology</i> , 2019, 5, 471.	7.1	426
77	CT Colonography in Preoperative Staging of Colon Cancer: Evaluation of FOxTROT Inclusion Criteria for Neoadjuvant Therapy. <i>American Journal of Roentgenology</i> , 2019, 212, 94-102.	2.2	22
78	Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. <i>JAMA Oncology</i> , 2019, 5, e185896.	7.1	347
79	Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes. <i>Cancer</i> , 2019, 125, 1441-1448.	4.1	28
80	Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. <i>Cancer Research</i> , 2019, 79, 1047-1053.	0.9	112
81	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. <i>Clinical Cancer Research</i> , 2019, 25, 2116-2126.	7.0	390
82	Outcomes of Low-Grade Appendiceal Mucinous Neoplasms with Remote Acellular Mucinous Peritoneal Deposits. <i>Annals of Surgical Oncology</i> , 2019, 26, 118-124.	1.5	18
83	FOLFICIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, e39-e52.	2.3	21
84	Gastric Carcinomas With Lymphoid Stroma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 453-462.	3.7	37
85	Poorly Differentiated Clusters Predict Colon Cancer Recurrence. <i>American Journal of Surgical Pathology</i> , 2018, 42, 705-714.	3.7	61
86	Potential immune priming of the tumor microenvironment with FOLFOX chemotherapy in locally advanced rectal cancer. <i>Oncolmmunology</i> , 2018, 7, e1435227.	4.6	16
87	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. <i>Clinical Cancer Research</i> , 2018, 24, 1326-1336.	7.0	281
88	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. <i>Cancer Cell</i> , 2018, 33, 125-136.e3.	16.8	589
89	Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. <i>JAMA Oncology</i> , 2018, 4, e180071.	7.1	404
90	Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome. <i>Familial Cancer</i> , 2018, 17, 71-77.	1.9	10

#	ARTICLE	IF	CITATIONS
91	Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations. <i>Familial Cancer</i> , 2018, 17, 225-228.	1.9	17
92	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. <i>Cancer Discovery</i> , 2018, 8, 49-58.	9.4	275
93	Spatial and phenotypic immune profiling of metastatic colon cancer. <i>JCI Insight</i> , 2018, 3, .	5.0	73
94	Are Enterocolic Mucosal Mast Cell Aggregates Clinically Relevant in Patients Without Suspected or Established Systemic Mastocytosis?. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1390-1395.	3.7	11
95	Acquired resistance to immunotherapy in MMR-D pancreatic cancer. , 2018, 6, 127.		27
96	Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3925-3930.	3.6	106
97	Tumor-Associated Macrophage Infiltration in Colorectal Cancer Liver Metastases is Associated With Better Outcome. <i>Annals of Surgical Oncology</i> , 2017, 24, 1835-1842.	1.5	61
98	Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. <i>Molecular Cancer Research</i> , 2017, 15, 708-713.	3.4	24
99	Molecular Screening for Lynch Syndrome in Young Patients With Colorectal Adenomas. <i>Clinical Colorectal Cancer</i> , 2017, 16, 173-177.	2.3	13
100	Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations. <i>Familial Cancer</i> , 2017, 16, 525-529.	1.9	18
101	Computed Tomography Image Texture: A Noninvasive Prognostic Marker of Hepatic Recurrence After Hepatectomy for Metastatic Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 2482-2490.	1.5	45
102	EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. <i>Pathology and Oncology Research</i> , 2017, 23, 673-677.	1.9	28
103	Diagnosing colorectal medullary carcinoma: interobserver variability and clinicopathological implications. <i>Human Pathology</i> , 2017, 62, 74-82.	2.0	17
104	Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphologyâ€“molecular associations: clinical and biological implications. <i>Modern Pathology</i> , 2017, 30, 599-609.	5.5	74
105	Clinical and genetic determinants of ovarian metastases from colorectal cancer. <i>Cancer</i> , 2017, 123, 1134-1143.	4.1	43
106	Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. <i>JCO Precision Oncology</i> , 2017, 2017, 1-17.	3.0	209
107	Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, E65-E72.	1.4	4
108	SMAD4 loss in colorectal cancer: Correlation with recurrence, chemoresistance, and immune infiltrate.. <i>Journal of Clinical Oncology</i> , 2017, 35, 587-587.	1.6	5

#	ARTICLE	IF	CITATIONS
109	Total neoadjuvant therapy for locally advanced rectal cancer.. Journal of Clinical Oncology, 2017, 35, 662-662.	1.6	3
110	Evolution in multimodality management of locally advanced rectal cancer.. Journal of Clinical Oncology, 2017, 35, 684-684.	1.6	1
111	MicroRNA-203 predicts human survival after resection of colorectal liver metastasis. Oncotarget, 2017, 8, 18821-18831.	1.8	19
112	Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma. Oncotarget, 2017, 8, 42487-42494.	1.8	10
113	Institutional variation in the thoroughness of pathologic assessment and pathologic complete response rates for locally advanced rectal cancers treated with neoadjuvant chemoradiation.. Journal of Clinical Oncology, 2017, 35, 696-696.	1.6	0
114	Poorly differentiated clusters as a prognostic marker at the invasive front of colon cancer.. Journal of Clinical Oncology, 2017, 35, 621-621.	1.6	1
115	Variability in genomic alterations between right- and left-sided microsatellite stable (MSS) metastatic colorectal cancer and impact on survival.. Journal of Clinical Oncology, 2017, 35, 3534-3534.	1.6	1
116	Total neoadjuvant chemotherapy to facilitate delivery and tolerance of systemic chemotherapy and response in locally advanced rectal cancer.. Journal of Clinical Oncology, 2017, 35, 3519-3519.	1.6	4
117	Recurrent, truncating <i>SOX9</i> mutations are associated with <i>SOX9</i> overexpression, <i>KRAS</i> mutation, and <i>TP53</i> wild type status in colorectal carcinoma. Oncotarget, 2016, 7, 50875-50882.	1.8	26
118	Detection of human norovirus in intestinal biopsies from immunocompromised transplant patients. Journal of General Virology, 2016, 97, 2291-2300.	2.9	85
119	Clinicopathologic Features of Colorectal Carcinoma in HIV-Positive Patients. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1098-1104.	2.5	9
120	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. Journal of Clinical Oncology, 2016, 34, 2141-2147.	1.6	204
121	ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance. Human Pathology, 2016, 53, 97-104.	2.0	18
122	Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 523-532.	2.8	65
123	Colorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients. Journal of Pediatric Surgery, 2016, 51, 1812-1817.	1.6	72
124	Distance to the anal verge is associated with pathologic complete response to neoadjuvant therapy in locally advanced rectal cancer. Journal of Surgical Oncology, 2016, 114, 637-641.	1.7	35
125	Expression of Markers of Hepatocellular Differentiation in Pancreatic Acinar Cell Neoplasms. American Journal of Clinical Pathology, 2016, 146, 163-169.	0.7	28
126	Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Modern Pathology, 2016, 29, 1433-1442.	5.5	144

#	ARTICLE	IF	CITATIONS
127	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. <i>Molecular Cancer Research</i> , 2016, 14, 296-301.	3.4	46
128	A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases. <i>Clinical Cancer Research</i> , 2016, 22, 2575-2582.	7.0	40
129	A Germline Variant on Chromosome 4q31.1 Associates with Susceptibility to Developing Colon Cancer Metastasis. <i>PLoS ONE</i> , 2016, 11, e0146435.	2.5	2
130	Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiation. <i>Oncotarget</i> , 2016, 7, 2159-2174.	1.8	24
131	Combined intrahepatic cholangiocarcinoma and hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2016, 5, 66-66.	1.2	33
132	Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. <i>Chinese Clinical Oncology</i> , 2016, 5, 62-62.	1.2	131
133	Carcinosarcoma of the bile duct: a case report and review of literature. <i>Hepatobiliary Surgery and Nutrition</i> , 2016, 5, 72-8.	1.5	2
134	The accuracy of pre-operative imaging in the management of hepatic cysts. <i>Hpb</i> , 2015, 17, 889-895.	0.3	16
135	The prognostic significance of CXCL1 hypersecretion by human colorectal cancer epithelia and myofibroblasts. <i>Journal of Translational Medicine</i> , 2015, 13, 199.	4.4	52
136	Resection Margin and Survival in 2368 Patients Undergoing Hepatic Resection for Metastatic Colorectal Cancer. <i>Annals of Surgery</i> , 2015, 262, 476-485.	4.2	156
137	Immunohistochemical Detection of the BRAF V600E Mutant Protein in Colorectal Neoplasms. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, 438-443.	1.2	17
138	Cholangiocarcinoma: Correlation between Molecular Profiling and Imaging Phenotypes. <i>PLoS ONE</i> , 2015, 10, e0132953.	2.5	50
139	Genetic Evidence That Intratumoral T-cell Proliferation and Activation Are Associated with Recurrence and Survival in Patients with Resected Colorectal Liver Metastases. <i>Cancer Immunology Research</i> , 2015, 3, 380-388.	3.4	30
140	Does Gadolinium-Based Contrast Material Improve Diagnostic Accuracy of Local Invasion in Rectal Cancer MRI? A Multireader Study. <i>American Journal of Roentgenology</i> , 2015, 204, W160-W167.	2.2	33
141	Evolving approach and clinical significance of detecting DNA mismatch repair deficiency in colorectal carcinoma. <i>Seminars in Diagnostic Pathology</i> , 2015, 32, 352-361.	1.5	47
142	Chemotherapy-Induced Splenic Volume Increase Is Independently Associated with Major Complications after Hepatic Resection for Metastatic Colorectal Cancer. <i>Journal of the American College of Surgeons</i> , 2015, 220, 271-280.	0.5	30
143	Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). <i>Modern Pathology</i> , 2015, 28, 1123-1129.	5.5	51
144	Mismatch repair deficient-crypts in non-neoplastic colonic mucosa in Lynch syndrome: insights from an illustrative case. <i>Familial Cancer</i> , 2015, 14, 61-68.	1.9	27

#	ARTICLE	IF	CITATIONS
145	AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants. <i>Molecular Cancer Research</i> , 2015, 13, 1003-1008.	3.4	20
146	Lymph Node Yield After Colectomy for Cancer. <i>Diseases of the Colon and Rectum</i> , 2015, 58, 288-293.	1.3	11
147	Identification of novel and potentially targetable receptor tyrosine kinase alterations in colorectal carcinoma using a 341 gene hybrid capture-based next-generation sequencing assay.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11071-11071.	1.6	0
148	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. <i>Genome Biology</i> , 2014, 15, 454.	8.8	296
149	<i>KRAS</i> mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. <i>Cancer</i> , 2014, 120, 3965-3971.	4.1	127
150	Immunohistochemical detection of ARID1A in colorectal carcinoma: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage. <i>Human Pathology</i> , 2014, 45, 2430-2436.	2.0	41
151	The Utility of Immunohistochemistry in Subtyping Adenocarcinoma of the Ampulla of Vater. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1371-1379.	3.7	113
152	Utilization of Colonoscopy and Pathology Reports for Identifying Patients Meeting the World Health Organization Criteria for Serrated Polyposis Syndrome. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 846-850.	1.3	9
153	Adenocarcinoma of the Minor Duodenal Papilla and Its Precursor Lesions. <i>American Journal of Surgical Pathology</i> , 2014, 38, 526-533.	3.7	19
154	Management and Outcome of Perianal Paget's Disease. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 747-751.	1.3	52
155	A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 60, 319-324.	3.7	83
156	Sclerosed hemangioma of the liver: Concordance of MRI features with histologic characteristics. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 39, 812-818.	3.4	22
157	Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 513-518.	1.6	375
158	A Retrospective Review of 126 High-Grade Neuroendocrine Carcinomas of the Colon and Rectum. <i>Annals of Surgical Oncology</i> , 2014, 21, 2956-2962.	1.5	123
159	Comparison of Tumor Regression Grade Systems for Locally Advanced Rectal Cancer After Multimodality Treatment. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	179
160	Ganetespib, a Novel Hsp90 Inhibitor in Patients With KRAS Mutated and Wild Type, Refractory Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 207-212.	2.3	37
161	Imaging and Clinicopathologic Features of Esophageal Gastrointestinal Stromal Tumors. <i>American Journal of Roentgenology</i> , 2014, 203, 306-314.	2.2	30
162	Imaging and management of a small cell lung cancer metastasis/adrenal adenoma collision tumor: a case report and review of the literature. <i>World Journal of Surgical Oncology</i> , 2014, 12, 45.	1.9	18

#	ARTICLE	IF	CITATIONS
163	Tumor MHC Class I Expression Improves the Prognostic Value of T-cell Density in Resected Colorectal Liver Metastases. <i>Cancer Immunology Research</i> , 2014, 2, 530-537.	3.4	43
164	p27 expression in post-treatment rectal cancer: a potential novel approach for predicting residual nodal disease. <i>American Journal of Surgery</i> , 2014, 208, 228-234.	1.8	2
165	Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome. <i>Familial Cancer</i> , 2014, 13, 459-467.	1.9	14
166	DNA Mismatch Repair Abnormalities in Acinar Cell Carcinoma of the Pancreas. <i>Pancreas</i> , 2014, 43, 1264-1270.	1.1	34
167	Liver and Bile Duct Cancer. , 2014, , 1373-1396.e8.		5
168	Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry. <i>Familial Cancer</i> , 2013, 12, 241-260.	1.9	88
169	Regulatory T Cell Infiltration Predicts Outcome Following Resection of Colorectal Cancer Liver Metastases. <i>Annals of Surgical Oncology</i> , 2013, 20, 946-955.	1.5	141
170	Locoregional Lymphadenectomy in the Surgical Management of Anorectal Melanoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 2339-2344.	1.5	45
171	Patients With Colorectal and Renal Cell Carcinoma Diagnoses Appear to Be at Risk for Additional Malignancies. <i>Clinical Colorectal Cancer</i> , 2013, 12, 23-27.	2.3	11
172	Preoperative Chemotherapy and the Risk of Hepatotoxicity and Morbidity after Liver Resection for Metastatic Colorectal Cancer: A Single Institution Experience. <i>Journal of the American College of Surgeons</i> , 2013, 216, 41-49.	0.5	77
173	Detailed Pathologic Characteristics of the Primary Colorectal Tumor Independently Predict Outcome after Hepatectomy for Metastases. <i>Annals of Surgical Oncology</i> , 2013, 20, 148-154.	1.5	43
174	What is the Significance of the Circumferential Margin in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy?. <i>Annals of Surgical Oncology</i> , 2013, 20, 1179-1184.	1.5	66
175	Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a ¹ H MRS study. <i>NMR in Biomedicine</i> , 2013, 26, 204-212.	2.8	5
176	Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoeexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency. <i>Modern Pathology</i> , 2013, 26, 131-138.	5.5	82
177	Neither FDG-PET Nor CT Can Distinguish Between a Pathological Complete Response and an Incomplete Response After Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. <i>Annals of Surgery</i> , 2013, 258, 289-295.	4.2	94
178	Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma. <i>Modern Pathology</i> , 2013, 26, 1197-1203.	5.5	22
179	Response to Neoadjuvant Therapy in Patients With Early Age-of-Onset Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 58-63.	1.3	7
180	Association of KRAS mutation with worse recurrence-free survival and site of metastatic progression after resection of hepatic colorectal metastases.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3609-3609.	1.6	1

#	ARTICLE	IF	CITATIONS
181	Characterization of rectal cancer in patients with Lynch syndrome.. Journal of Clinical Oncology, 2013, 31, 350-350.	1.6	1
182	Influence of KRAS mutation on recurrence patterns in patients undergoing hepatic resection of colorectal metastases.. Journal of Clinical Oncology, 2013, 31, 398-398.	1.6	1
183	Gene Expression Profiles Accurately Predict Outcome Following Liver Resection in Patients with Metastatic Colorectal Cancer. PLoS ONE, 2013, 8, e81680.	2.5	33
184	Characterization of colorectal cancer (CRC) in Lynch syndrome (LS) patients with <i>MSH6</i> or <i>PMS2</i> mutations.. Journal of Clinical Oncology, 2013, 31, 1555-1555.	1.6	0
185	Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas. Journal of Clinical Oncology, 2012, 30, 2956-2962.	1.6	254
186	Juvenile Polyposis Syndrome Presenting With Familial Gastric Cancer and Massive Gastric Polyposis. Journal of Clinical Oncology, 2012, 30, e229-e232.	1.6	9
187	FDG-PET Assessment of Rectal Cancer Response to Neoadjuvant Chemoradiotherapy Is Not Associated With Long-Term Prognosis. Diseases of the Colon and Rectum, 2012, 55, 378-386.	1.3	26
188	DNA Mismatch Repair Deficiency in Breast Carcinoma. American Journal of Surgical Pathology, 2012, 36, 1700-1708.	3.7	43
189	Hypoxia-Related Proteins in Patients With Rectal Cancer Undergoing Neoadjuvant Combined Modality Therapy. Diseases of the Colon and Rectum, 2012, 55, 990-995.	1.3	23
190	Whole-Mount Pathologic Analysis of Rectal Cancer Following Neoadjuvant Therapy. Annals of Surgery, 2012, 256, 274-279.	4.2	38
191	Early Postoperative Intraperitoneal Chemotherapy Following Cytoreductive Surgery for Appendiceal Mucinous Neoplasms With Isolated Peritoneal Metastasis. Diseases of the Colon and Rectum, 2012, 55, 407-415.	1.3	16
192	Rate of Residual Disease After Complete Endoscopic Resection of Malignant Colonic Polyp. Diseases of the Colon and Rectum, 2012, 55, 122-127.	1.3	75
193	Pulmonary Recurrence Predominates After Combined Modality Therapy for Rectal Cancer. Annals of Surgery, 2012, 256, 111-116.	4.2	63
194	Clinicopathologic Analysis of Matched Primary and Recurrent Endometrial Carcinoma. American Journal of Surgical Pathology, 2012, 36, 1771-1781.	3.7	22
195	The Prevalence of Thyroid Cancer and Benign Thyroid Disease in Patients With Familial Adenomatous Polyposis May Be Higher Than Previously Recognized. Clinical Colorectal Cancer, 2012, 11, 304-308.	2.3	52
196	CXCR4 Expression Predicts Patient Outcome and Recurrence Patterns after Hepatic Resection for Colorectal Liver Metastases. Annals of Surgical Oncology, 2012, 19, 339-346.	1.5	43
197	Resection of Adrenocortical Carcinoma Liver Metastasis: Is it Justified?. Annals of Surgical Oncology, 2012, 19, 2643-2651.	1.5	64
198	Pathologic Response to Preoperative Chemotherapy in Colorectal Liver Metastases: Fibrosis, not Necrosis, Predicts Outcome. Annals of Surgical Oncology, 2012, 19, 2797-2804.	1.5	53

#	ARTICLE	IF	CITATIONS
199	Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. <i>Human Pathology</i> , 2012, 43, 1677-1687.	2.0	93
200	TNM staging of colorectal carcinoma: issues and caveats. <i>Seminars in Diagnostic Pathology</i> , 2012, 29, 142-153.	1.5	24
201	A High Degree of LINE-1 Hypomethylation Is a Unique Feature of Early-Onset Colorectal Cancer. <i>PLoS ONE</i> , 2012, 7, e45357.	2.5	164
202	Systematic Immunohistochemistry Screening for Lynch Syndrome in Early Age-of-Onset Colorectal Cancer Patients Undergoing Surgical Resection. <i>Journal of the American College of Surgeons</i> , 2012, 214, 61-67.	0.5	32
203	Lymph Node Staging in Colorectal Cancer: Revisiting the Benchmark of at Least 12 Lymph Nodes in R0 Resection. <i>Journal of the American College of Surgeons</i> , 2012, 214, 348-355.	0.5	57
204	Is there any significant difference between tumor regression grade systems of rectal cancer?. <i>Journal of Clinical Oncology</i> , 2012, 30, 3583-3583.	1.6	0
205	Synchronous Epithelial and Neuroendocrine Cancers of the Pancreas: Case Series of a Rare Occurrence. <i>Clinical Colorectal Cancer</i> , 2011, 10, 146-150.	2.3	3
206	A single arm phase II study of a Far-Eastern traditional herbal formulation (sho-sai-ko-to or) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462 Td	4.1	50
207	Immunohistochemical Staining for DNA Mismatch Repair Proteins in Intestinal Tract Carcinoma. <i>American Journal of Surgical Pathology</i> , 2011, 35, 447-454.	3.7	82
208	A Predictive Model for Lymph Node Yield in Colon Cancer Resection Specimens. <i>Annals of Surgery</i> , 2011, 253, 318-322.	4.2	45
209	Significance of Acellular Mucin Pools in Rectal Carcinoma After Neoadjuvant Chemoradiotherapy. <i>American Journal of Surgical Pathology</i> , 2011, 35, 127-134.	3.7	90
210	Synchronous Breast Cancers With Different Morphologic and Molecular Phenotypes Occurring in Lynch Syndrome. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1743-1748.	3.7	11
211	High-grade dysplasia of the cystic duct margin in the absence of malignancy after cholecystectomy. <i>Hpb</i> , 2011, 13, 865-868.	0.3	23
212	Liver angiomyolipomas: A clinical, radiologic, and pathologic analysis of 22 patients from a single center. <i>Surgery</i> , 2011, 150, 557-567.	1.9	8
213	Folate receptor-1 expression in resectable hepatic colorectal cancer metastases: patterns and significance. <i>Modern Pathology</i> , 2011, 24, 1221-1228.	5.5	48
214	Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response. <i>Annals of Surgical Oncology</i> , 2011, 18, 2192-2199.	1.5	76
215	Evaluation of 18F-FDG-PET for Early Detection of Suboptimal Response of Rectal Cancer to Preoperative Chemoradiotherapy: A Prospective Analysis. <i>Annals of Surgical Oncology</i> , 2011, 18, 2783-2789.	1.5	34
216	Variable MR imaging appearances of focal nodular hyperplasia in pediatric cancer patients. <i>Pediatric Radiology</i> , 2011, 41, 335-340.	2.0	16

#	ARTICLE	IF	CITATIONS
217	A Woman with Remotely Treated Pancreas Cancer and New Abdominal Pain: A Discussion of Evaluation and Management. <i>Journal of Gastrointestinal Cancer</i> , 2011, 42, 236-240.	1.3	1
218	Challenging the Feasibility and Clinical Significance of Current Guidelines on Lymph Node Examination in Rectal Cancer in the Era of Neoadjuvant Therapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 4568-4573.	1.6	80
219	Acinar Cell Carcinoma of the Pancreas: New Genetic and Treatment Insights into a Rare Malignancy. <i>Oncologist</i> , 2011, 16, 1714-1720.	3.7	121
220	Pancreatic islet cell carcinoma presenting with concurrent Cushing's and Zollinger-Ellison syndromes: case series and literature review. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 246-252.	1.6	6
221	KRAS Mutation Correlates With Accelerated Metastatic Progression in Patients With Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2010, 17, 572-578.	1.5	159
222	Effects of Obesity in Rectal Cancer Surgery. <i>Journal of the American College of Surgeons</i> , 2010, 211, 55-60.	0.5	64
223	Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. <i>Cancer</i> , 2010, 116, 1502-1509.	4.1	165
224	Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4240-4246.	1.6	129
225	p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. <i>Modern Pathology</i> , 2010, 23, 80-92.	5.5	87
226	Improved Testing for Microsatellite Instability in Colorectal Cancer Using a Simplified 3-Marker Assay. <i>Annals of Surgical Oncology</i> , 2010, 17, 3370-3378.	1.5	15
227	Use of immunohistochemistry for IgG4 in the distinction of autoimmune pancreatitis from peritumoral pancreatitis. <i>Human Pathology</i> , 2010, 41, 643-652.	2.0	128
228	DNA Mismatch Repair Deficiency in Ampullary Carcinoma. <i>American Journal of Clinical Pathology</i> , 2010, 133, 772-780.	0.7	38
229	An Update on Tumors of the Anal Canal. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 1601-1611.	2.5	68
230	Feasibility of ex Vivo FDG PET of the Colon. <i>Radiology</i> , 2009, 252, 232-239.	7.3	15
231	Scirrhous Metastases to the Gastrointestinal Tract at CT: The Malignant Target Sign. <i>American Journal of Roentgenology</i> , 2009, 192, 936-940.	2.2	18
232	T Cell Infiltrate Predicts Long-Term Survival Following Resection of Colorectal Cancer Liver Metastases. <i>Annals of Surgical Oncology</i> , 2009, 16, 2524-2530.	1.5	116
233	Defining Surgical Indications for Type I Gastric Carcinoid Tumor. <i>Annals of Surgical Oncology</i> , 2009, 16, 3154-3160.	1.5	84
234	Immunohistochemistry as First-line Screening for Detecting Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1639-1645.	3.7	155

#	ARTICLE	IF	CITATIONS
235	Long-Term Survival After Transanal Excision of T1 Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 577-582.	1.3	151
236	Towards Identification of Hereditary DNA Mismatch Repair Deficiency: Sebaceous Neoplasm Warrants Routine Immunohistochemical Screening Regardless of Patient's Age or Other Clinical Characteristics. <i>American Journal of Surgical Pathology</i> , 2009, 33, 934-944.	3.7	76
237	Sphincter Preservation in Low Rectal Cancer is Facilitated by Preoperative Chemoradiation and Intersphincteric Dissection. <i>Annals of Surgery</i> , 2009, 249, 236-242.	4.2	206
238	Prognostic Significance of Localized Extra-appendiceal Mucin Deposition in Appendiceal Mucinous Neoplasms. <i>American Journal of Surgical Pathology</i> , 2009, 33, 248-255.	3.7	154
239	Operative Blood Loss Independently Predicts Recurrence and Survival After Resection of Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2009, 249, 617-623.	4.2	355
240	Selection of Endometrial Carcinomas for DNA Mismatch Repair Protein Immunohistochemistry Using Patient Age and Tumor Morphology Enhances Detection of Mismatch Repair Abnormalities. <i>American Journal of Surgical Pathology</i> , 2009, 33, 925-933.	3.7	178
241	Squamous-cell Carcinoma of the Anal Canal: Predictors of Treatment Outcome. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 147-153.	1.3	100
242	Squamous-cell Carcinoma of the Anal Canal: Predictors of Treatment Outcome. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 620.	1.3	0
243	Identification of Patients with High-Risk Stage II Colon Cancer for Adjuvant Therapy. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 503-507.	1.3	211
244	Predictive clinicopathologic factors for limited response of T3 rectal cancer to combined modality therapy. <i>International Journal of Colorectal Disease</i> , 2008, 23, 243-249.	2.2	22
245	Expression of P53, P27 and Ki67 in colorectal cancer patients of various ethnic origins: Clinical and tissue microarray based analysis. <i>Journal of Surgical Oncology</i> , 2008, 97, 416-422.	1.7	11
246	Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. <i>Cancer</i> , 2008, 113, 57-64.	4.1	228
247	A Novel Prognostic Nomogram Is More Accurate than Conventional Staging Systems for Predicting Survival after Resection of Hepatocellular Carcinoma. <i>Journal of the American College of Surgeons</i> , 2008, 206, 281-291.	0.5	114
248	Preoperative Radiographic Assessment of Hepatic Steatosis with Histologic Correlation. <i>Journal of the American College of Surgeons</i> , 2008, 206, 480-488.	0.5	87
249	Pathologic Complete Response to Neoadjuvant FOLFOX in Combination with Bevacizumab in Unresectable Metastatic Colorectal Carcinoma. <i>Clinical Colorectal Cancer</i> , 2008, 7, 140-143.	2.3	3
250	Collision Tumor of the Large Bowel in the Context of Advanced Pregnancy and Ulcerative Colitis. <i>Clinical Colorectal Cancer</i> , 2008, 7, 402-405.	2.3	10
251	Immunohistochemistry versus Microsatellite Instability Testing For Screening Colorectal Cancer Patients at Risk For Hereditary Nonpolyposis Colorectal Cancer Syndrome. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 293-300.	2.8	549
252	Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. <i>Human Pathology</i> , 2008, 39, 116-125.	2.0	143

#	ARTICLE	IF	CITATIONS
253	Immunohistochemical expression of folate receptor β in colorectal carcinoma: patterns and biological significance. <i>Human Pathology</i> , 2008, 39, 498-505.	2.0	102
254	Individualized Prediction of Colon Cancer Recurrence Using a Nomogram. <i>Journal of Clinical Oncology</i> , 2008, 26, 380-385.	1.6	244
255	Prognostic Implications of the Distribution of Lymph Node Metastases in Rectal Cancer After Neoadjuvant Chemoradiotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 2106-2111.	1.6	90
256	The Signatures of Autozygosity among Patients with Colorectal Cancer. <i>Cancer Research</i> , 2008, 68, 2610-2621.	0.9	47
257	Intramucosal Poorly Differentiated Colorectal Carcinoma: Can it be Managed Conservatively?. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1586-1588.	3.7	20
258	Is Nonsmall Cell Type High-grade Neuroendocrine Carcinoma of the Tubular Gastrointestinal Tract a Distinct Disease Entity?. <i>American Journal of Surgical Pathology</i> , 2008, 32, 719-731.	3.7	166
259	Pathologic Classification and Clinical Behavior of the Spectrum of Goblet Cell Carcinoid Tumors of the Appendix. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1429-1443.	3.7	284
260	Utility of Immunohistochemistry in Predicting Microsatellite Instability in Endometrial Carcinoma. <i>American Journal of Surgical Pathology</i> , 2007, 31, 744-751.	3.7	121
261	Single-amplicon MSH2 A636P Mutation Testing in Ashkenazi Jewish Patients With Colorectal Cancer. <i>Annals of Surgery</i> , 2007, 245, 560-565.	4.2	11
262	A Prospective Pathologic Analysis Using Whole-Mount Sections of Rectal Cancer Following Preoperative Combined Modality Therapy. <i>Annals of Surgery</i> , 2007, 245, 88-93.	4.2	123
263	Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. <i>Cancer Letters</i> , 2007, 248, 219-228.	7.2	153
264	Differential expression of β -methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance. <i>Human Pathology</i> , 2007, 38, 850-856.	2.0	26
265	Predictive Molecular Markers for Colorectal Cancer Patients With Resected Liver Metastasis and Adjuvant Chemotherapy. <i>Gastroenterology</i> , 2007, 133, 1831-1839.	1.3	18
266	Carcinoid of the Rectum Risk Stratification (CaRRS): A Strategy for Preoperative Outcome Assessment. <i>Annals of Surgical Oncology</i> , 2007, 14, 396-404.	1.5	71
267	Carcinoid of the Rectum Risk Stratification (CaRRS): A Strategy for Preoperative Outcome Assessment. <i>Annals of Surgical Oncology</i> , 2007, 14, 1735-1743.	1.5	86
268	Squamous-Cell Carcinoma of the Rectum: A Rare but Curable Tumor. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 1393-1400.	1.3	87
269	Limitations of Early Rectal Cancer Nodal Staging may Explain Failure after Local Excision. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 1520-1525.	1.3	93
270	Idiopathic Cholestasis as a Paraneoplastic Phenomenon in Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 77-82.	1.4	33

#	ARTICLE	IF	CITATIONS
271	The Role of Abdominoperineal Resection as Surgical Therapy for Anorectal Melanoma. <i>Annals of Surgery</i> , 2006, 244, 1012-1017.	4.2	159
272	A Pathologic Complete Response of Rectal Cancer to Preoperative Combined-Modality Therapy Results in Improved Oncological Outcome Compared With Those Who Achieve No Downstaging on the Basis of Preoperative Endorectal Ultrasonography. <i>Annals of Surgical Oncology</i> , 2006, 13, 1047-1053.	1.5	160
273	Extranodal follicular dendritic cell sarcoma: clinical, pathologic, and histogenetic characteristics of an underrecognized disease entity. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 449, 148-158.	2.8	118
274	Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. <i>Cancer</i> , 2006, 106, 1857-1862.	4.1	34
275	Predictors of Recurrence in Patients With T2 and Early T3, N0 Adenocarcinoma of the Rectum Treated by Surgery Alone. <i>Journal of Clinical Oncology</i> , 2006, 24, 4078-4084.	1.6	80
276	The Activity of Sunitinib against Gastrointestinal Stromal Tumor Seems to be Distinct from Its Antiangiogenic Effects: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 6203-6204.	7.0	29
277	Relationship of Gene Expression and Chromosomal Abnormalities in Colorectal Cancer. <i>Cancer Research</i> , 2006, 66, 2129-2137.	0.9	231
278	GRO1± Is Highly Expressed in Adenocarcinoma of the Colon and Down-Regulates Fibulin-1. <i>Clinical Cancer Research</i> , 2006, 12, 5951-5959.	7.0	54
279	Long-term Oncologic Outcome Following Preoperative Combined Modality Therapy and Total Mesorectal Excision of Locally Advanced Rectal Cancer. <i>Annals of Surgery</i> , 2005, 241, 829-838.	4.2	341
280	Virus-Associated Trichodysplasia Spinulosa. <i>American Journal of Surgical Pathology</i> , 2005, 29, 241-246.	3.7	59
281	Long-term Survival Following Treatment of Pseudomyxoma Peritonei. <i>Annals of Surgery</i> , 2005, 241, 300-308.	4.2	302
282	Value of Immunohistochemical Detection of DNA Mismatch Repair Proteins in Predicting Germline Mutation in Hereditary Colorectal Neoplasms. <i>American Journal of Surgical Pathology</i> , 2005, 29, 96-104.	3.7	136
283	Distinction of endometrial stromal sarcomas from "hemangiopericytomatous" tumors using a panel of immunohistochemical stains. <i>Modern Pathology</i> , 2005, 18, 40-47.	5.5	77
284	Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. <i>Modern Pathology</i> , 2005, 18, 1350-1356.	5.5	146
285	Metastases to the Breast from Primary Pancreatic Cancer. <i>Breast Journal</i> , 2005, 11, 503-503.	1.0	0
286	Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma. <i>Cancer</i> , 2005, 104, 1948-1955.	4.1	123
287	Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 447, 828-834.	2.8	29
288	Operative Salvage for Locoregional Recurrent Colon Cancer After Curative Resection: An Analysis of 100 Cases. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 897-909.	1.3	119

#	ARTICLE	IF	CITATIONS
289	Surgical Salvage of Recurrent Rectal Cancer After Transanal Excision. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 1169-1175.	1.3	153
290	An Increasingly Common Challenge: Management of the Complete Responder With Multi-Focal Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 1799-1802.	1.6	12
291	Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry. <i>Journal of Clinical Oncology</i> , 2005, 23, 1803-1810.	1.6	1,050
292	Clinical Examination Following Preoperative Chemoradiation for Rectal Cancer Is Not a Reliable Surrogate End Point. <i>Journal of Clinical Oncology</i> , 2005, 23, 3475-3479.	1.6	161
293	Response of stage IV anal mucosal melanoma to chemotherapy. <i>Lancet Oncology</i> , The, 2005, 6, 438-439.	10.7	39
294	Globular hepatic amyloid: a diagnostic peculiarity that bears clinical significance. <i>Human Pathology</i> , 2005, 36, 845-849.	2.0	32
295	Expression of p27 in Residual Rectal Cancer after Preoperative Chemoradiation Predicts Long-term Outcome. <i>Annals of Surgical Oncology</i> , 2004, 11, 955-961.	1.5	24
296	Residual Mesorectal Lymph Node Involvement Following Neoadjuvant Combined-Modality Therapy: Rationale for Radical Resection?. <i>Annals of Surgical Oncology</i> , 2004, 11, 187-191.	1.5	79
297	CASE REPORT: Ileal Diverticulitis: Clinical and Radiographic Presentation. <i>Digestive Diseases and Sciences</i> , 2004, 49, 498-502.	2.3	9
298	The utility of immunohistochemical detection of DNA mismatch repair gene proteins. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004, 445, 431-441.	2.8	96
299	Rate of Pathologic Complete Response With Increased Interval Between Preoperative Combined Modality Therapy and Rectal Cancer Resection. <i>Diseases of the Colon and Rectum</i> , 2004, 47, 279-286.	1.3	234
300	Lymph node metastasis in T1 adenocarcinoma of the colon and rectum. <i>Journal of Gastrointestinal Surgery</i> , 2004, 8, 1032-1040.	1.7	154
301	Lymphohistiocytoid Mesothelioma: A Clinical, Immunohistochemical and Ultrastructural Study of Four Cases and Literature Review. <i>Ultrastructural Pathology</i> , 2004, 28, 213-228.	0.9	25
302	Patterns of Morphologic Alteration in Residual Rectal Carcinoma Following Preoperative Chemoradiation and Their Association With Long-term Outcome. <i>American Journal of Surgical Pathology</i> , 2004, 28, 215-223.	3.7	182
303	Whorls of Intermediate Filaments With Entrapped Neurosecretory Granules Correspond to the "Rhabdoid" Inclusions Seen in Pancreatic Endocrine Neoplasms. <i>American Journal of Surgical Pathology</i> , 2004, 28, 271-273.	3.7	23
304	HER 2/neu expression and gene amplification in colon cancer. <i>International Journal of Cancer</i> , 2003, 105, 796-802.	5.1	93
305	MSH6 germline mutations are rare in colorectal cancer families. <i>International Journal of Cancer</i> , 2003, 107, 571-579.	5.1	53
306	Value of Histopathology in Predicting Microsatellite Instability in Hereditary Nonpolyposis Colorectal Cancer and Sporadic Colorectal Cancer. <i>American Journal of Surgical Pathology</i> , 2003, 27, 1407-1417.	3.7	200

#	ARTICLE	IF	CITATIONS
307	Metastatic Epithelioid Gastrointestinal Stromal Tumor: Yet Another Tumor with Anemone Cell Features. <i>Ultrastructural Pathology</i> , 2003, 27, 95-100.	0.9	5
308	Pathogenesis of Colloid (Pure Mucinous) Carcinoma of Exocrine Organs. <i>American Journal of Surgical Pathology</i> , 2003, 27, 571-578.	3.7	171
309	Deciduoid Mesothelioma: A Report of 5 Cases and Literature Review. <i>Ultrastructural Pathology</i> , 2002, 26, 355-363.	0.9	59
310	BLM Heterozygosity and the Risk of Colorectal Cancer. <i>Science</i> , 2002, 297, 2013-2013.	12.6	174
311	Increased Endocrine Cells in Treated Rectal Adenocarcinomas. <i>American Journal of Surgical Pathology</i> , 2002, 26, 863-872.	3.7	91
312	Primary Follicular Lymphoma of the Gastrointestinal Tract. <i>American Journal of Surgical Pathology</i> , 2002, 26, 216-224.	3.7	155
313	Histologic Classification of Tumor-Infiltrating Lymphocytes in Primary Cutaneous Malignant Melanoma. <i>American Journal of Clinical Pathology</i> , 2001, 115, 856-860.	0.7	77